|
|
|
|
|
Medeiros,M.A.; Canteras,N.S.; Suchecki,D.; Mello,L.E.A.M.. |
In laboratory animals, acupuncture needs to be performed on either anesthetized or, if unanesthetized, restrained subjects. Both procedures up-regulate c-Fos expression in several areas of the central nervous system, representing therefore a major pitfall for the assessment of c-Fos expression induced by electroacupuncture. Thus, in order to reduce the effect of acute restraint we used a protocol of repeated restraint for the assessment of the brain areas activated by electroacupuncture in adult male Wistar rats weighing 180-230 g. Repeated immobilization protocols (6 days, 1 h/day and 13 days, 2 h/day) were used to reduce the effect of acute immobilization stress on the c-Fos expression induced by electroacupuncture at the Zusanli point (EA36S). Animals... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Acupuncture; Zusanli point; Immediate early genes; C-Fos; Restraint; Habituation. |
Ano: 2003 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2003001200009 |
| |
|
| |
|
| |
|
|
Ferro,M.M.; Angelucci,M.E.M.; Anselmo-Franci,J.A.; Canteras,N.S.; Da Cunha,C.. |
There is a great concern in the literature for the development of neuroprotectant drugs to treat Parkinson's disease. Since anesthetic drugs have hyperpolarizing properties, they can possibly act as neuroprotectants. In the present study, we have investigated the neuroprotective effect of a mixture of ketamine (85 mg/kg) and xylazine (3 mg/kg) (K/X) on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 6-hydroxydopamine (6-OHDA) rat models of Parkinson's disease. The bilateral infusion of MPTP (100 µg/side) or 6-OHDA (10 µg/side) into the substantia nigra pars compacta of adult male Wistar rats under thiopental anesthesia caused a modest (~67%) or severe (~91%) loss of tyrosine hydroxylase-immunostained cells, respectively. On the other hand, an... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Neuroprotection 6-Hydroxydopamine 1-Methyl-4-phenyl-1; 2; 3; 6- tetrahydropyridine Ketamine Parkinson's disease. |
Ano: 2007 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000100012 |
| |
|
|
|